Treating osteoarthrosis in terms of the safety of pharmacotherapy

It is shown that of great importance in osteoarthrosis (OA) is the use of hyaluronic acid preparations and oral chondroprotectors that produce not only symptomatic, but also structurally modifying effects. Combined therapy using these agents makes it possible to enhance the efficiency of the therapy...

Full description

Bibliographic Details
Main Author: A E Karateyev
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2009-03-01
Series:Современная ревматология
Online Access:https://mrj.ima-press.net/mrj/article/view/209
_version_ 1797876883470155776
author A E Karateyev
author_facet A E Karateyev
author_sort A E Karateyev
collection DOAJ
description It is shown that of great importance in osteoarthrosis (OA) is the use of hyaluronic acid preparations and oral chondroprotectors that produce not only symptomatic, but also structurally modifying effects. Combined therapy using these agents makes it possible to enhance the efficiency of the therapy for OA and to reduce a risk of drug-induced complications due to the decreased requirements for nonsteroidal anti-inflammatory drugs. The data showing the benefits of a low molecular-weight hyaluronic acid preparation (Hyalgan®) and an agent based on the unsaponifiable compounds of avocado and soybean (Piascledine®) and evidence for their efficacy and safety are given.
first_indexed 2024-04-10T02:08:30Z
format Article
id doaj.art-28449e04584c44dd9e7a4241b4c08366
institution Directory Open Access Journal
issn 1996-7012
2310-158X
language Russian
last_indexed 2024-04-10T02:08:30Z
publishDate 2009-03-01
publisher IMA-PRESS LLC
record_format Article
series Современная ревматология
spelling doaj.art-28449e04584c44dd9e7a4241b4c083662023-03-13T08:39:20ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2009-03-0131515710.14412/1996-7012-2009-5241514Treating osteoarthrosis in terms of the safety of pharmacotherapyA E KarateyevIt is shown that of great importance in osteoarthrosis (OA) is the use of hyaluronic acid preparations and oral chondroprotectors that produce not only symptomatic, but also structurally modifying effects. Combined therapy using these agents makes it possible to enhance the efficiency of the therapy for OA and to reduce a risk of drug-induced complications due to the decreased requirements for nonsteroidal anti-inflammatory drugs. The data showing the benefits of a low molecular-weight hyaluronic acid preparation (Hyalgan®) and an agent based on the unsaponifiable compounds of avocado and soybean (Piascledine®) and evidence for their efficacy and safety are given.https://mrj.ima-press.net/mrj/article/view/209
spellingShingle A E Karateyev
Treating osteoarthrosis in terms of the safety of pharmacotherapy
Современная ревматология
title Treating osteoarthrosis in terms of the safety of pharmacotherapy
title_full Treating osteoarthrosis in terms of the safety of pharmacotherapy
title_fullStr Treating osteoarthrosis in terms of the safety of pharmacotherapy
title_full_unstemmed Treating osteoarthrosis in terms of the safety of pharmacotherapy
title_short Treating osteoarthrosis in terms of the safety of pharmacotherapy
title_sort treating osteoarthrosis in terms of the safety of pharmacotherapy
url https://mrj.ima-press.net/mrj/article/view/209
work_keys_str_mv AT aekarateyev treatingosteoarthrosisintermsofthesafetyofpharmacotherapy